Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:01:58 2024-05-28 pm EDT 		After market 08:00:00 pm
28.3 USD -2.01% Intraday chart for Pfizer, Inc. 28.1 -0.71%
May. 27 US, European nations consider vaccinating workers exposed to bird flu RE
May. 24 Novavax awaits FDA decision on whether its next COVID shot can be offered in US RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 216,827 204,605 331,440 287,626 162,560 160,365 - -
Enterprise Value (EV) 1 259,147 232,220 338,807 300,723 221,758 218,477 212,232 205,429
P/E ratio 13.7 x 21.5 x 15.3 x 9.37 x 77.8 x 21.5 x 14.5 x 13.1 x
Yield 3.68% 4.13% 2.64% 3.14% 5.73% 5.9% 6.01% 6.14%
Capitalization / Revenue 4.19 x 4.88 x 4.08 x 2.87 x 2.78 x 2.65 x 2.56 x 2.53 x
EV / Revenue 5.01 x 5.54 x 4.17 x 3 x 3.79 x 3.61 x 3.38 x 3.24 x
EV / EBITDA 12.3 x 13 x 13.3 x 7.1 x 14.2 x 10.2 x 8.9 x 8.22 x
EV / FCF 24.9 x 19.1 x 11.3 x 11.6 x 46.3 x 20.3 x 14.6 x 12.9 x
FCF Yield 4.02% 5.23% 8.82% 8.66% 2.16% 4.94% 6.87% 7.73%
Price to Book 3.43 x 3.24 x 4.3 x 3 x 1.83 x 1.85 x 1.83 x 1.8 x
Nbr of stocks (in thousands) 5,534,122 5,558,397 5,612,867 5,613,315 5,646,413 5,666,593 - -
Reference price 2 39.18 36.81 59.05 51.24 28.79 28.30 28.30 28.30
Announcement Date 1/28/20 2/2/21 2/8/22 1/31/23 1/30/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 51,750 41,908 81,288 100,330 58,496 60,504 62,718 63,446
EBITDA 1 21,097 17,801 25,426 42,336 15,590 21,401 23,856 24,982
EBIT 1 19,420 13,024 20,235 37,272 9,300 16,809 19,044 20,263
Operating Margin 37.53% 31.08% 24.89% 37.15% 15.9% 27.78% 30.36% 31.94%
Earnings before Tax (EBT) 1 17,682 7,497 24,311 34,729 1,058 11,020 13,999 14,115
Net income 1 16,273 9,616 21,979 31,372 2,119 6,882 10,514 11,497
Net margin 31.45% 22.95% 27.04% 31.27% 3.62% 11.38% 16.76% 18.12%
EPS 2 2.870 1.710 3.850 5.470 0.3700 1.314 1.948 2.164
Free Cash Flow 1 10,412 12,151 29,869 26,031 4,793 10,786 14,571 15,876
FCF margin 20.12% 28.99% 36.74% 25.95% 8.19% 17.83% 23.23% 25.02%
FCF Conversion (EBITDA) 49.35% 68.26% 117.47% 61.49% 30.74% 50.4% 61.08% 63.55%
FCF Conversion (Net income) 63.98% 126.36% 135.9% 82.98% 226.19% 156.72% 138.59% 138.09%
Dividend per Share 2 1.440 1.520 1.560 1.610 1.650 1.671 1.701 1.737
Announcement Date 1/28/20 2/2/21 2/8/22 1/31/23 1/30/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 23,838 25,661 27,742 22,638 24,290 18,282 12,734 13,232 14,249 14,879 13,053 14,851 17,769 15,680 13,725
EBITDA 1 4,403 11,135 13,583 10,325 6,772 7,857 4,925 -1,244 1,340 - 3,758 4,680 4,537 - -
EBIT 1 3,126 9,948 12,408 9,142 5,253 6,370 3,319 -1,625 -330 5,912 3,423 3,804 3,977 - -
Operating Margin 13.11% 38.77% 44.73% 40.38% 21.63% 34.84% 26.06% -12.28% -2.32% 39.73% 26.22% 25.62% 22.38% - -
Earnings before Tax (EBT) 1 - 9,050 - - 5,231 - - -3,352 -4,129 3,421 1,962 2,926 3,380 - -
Net income 1 3,393 7,864 9,906 8,608 4,995 5,543 2,327 -2,382 -3,369 3,115 1,451 1,957 2,545 - -
Net margin 14.23% 30.65% 35.71% 38.02% 20.56% 30.32% 18.27% -18% -23.64% 20.94% 11.11% 13.18% 14.32% - -
EPS 2 0.5900 1.370 1.730 1.510 0.8700 0.9700 0.4100 -0.4200 -0.6000 0.5500 0.2412 0.3502 0.4517 - -
Dividend per Share 2 0.3900 0.4000 0.4000 0.4000 0.4100 0.4100 0.4100 0.4100 0.4200 0.4200 0.4159 0.4159 0.4159 0.4220 0.4220
Announcement Date 2/8/22 5/3/22 7/28/22 11/1/22 1/31/23 5/2/23 8/1/23 10/31/23 1/30/24 5/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 42,320 27,615 7,367 13,097 59,198 58,112 51,868 45,065
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.006 x 1.551 x 0.2897 x 0.3094 x 3.797 x 2.715 x 2.174 x 1.804 x
Free Cash Flow 1 10,412 12,151 29,869 26,031 4,793 10,786 14,571 15,876
ROE (net income / shareholders' equity) 25.7% 15.2% 31.3% 43.5% 11.4% 14% 16.6% 17%
ROA (Net income/ Total Assets) 9.96% 5.98% 13.1% 19.9% 4.96% 4.59% 5.8% 6.44%
Assets 1 163,456 160,910 167,853 157,490 42,750 150,025 181,221 178,414
Book Value Per Share 2 11.40 11.40 13.70 17.10 15.80 15.30 15.50 15.70
Cash Flow per Share 2 2.220 2.560 5.710 5.110 1.520 2.920 3.320 3.260
Capex 1 2,176 2,252 2,711 3,236 3,907 2,764 2,901 2,911
Capex / Sales 4.2% 5.37% 3.34% 3.23% 6.68% 4.57% 4.63% 4.59%
Announcement Date 1/28/20 2/2/21 2/8/22 1/31/23 1/30/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Pfizer, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.3 USD
Average target price
31.92 USD
Spread / Average Target
+12.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 160B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 347B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 319B
ABBVIE INC. Stock AbbVie Inc.
+0.24% 274B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.53% 238B
NOVARTIS AG Stock Novartis AG
+7.00% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-6.46% 203B
AMGEN INC. Stock Amgen Inc.
+4.23% 161B
SANOFI Stock Sanofi
-1.86% 120B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. Financials Pfizer, Inc.